Repurposing a cholesterol drug candidate for cholestatic liver disease
June 19, 2013
Lumena Pharmaceuticals Inc. is converting a compound previously tested as a cholesterol-lowering agent into an experimental treatment for cholestatic liver diseases. The molecule inhibits a so-called transporter that normally helps the body recycle bile acid.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.